These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27574472)

  • 1. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
    Singer JW; Al-Fayoumi S; Ma H; Komrokji RS; Mesa R; Verstovsek S
    J Exp Pharmacol; 2016; 8():11-9. PubMed ID: 27574472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of pacritinib in myelofibrosis.
    Verstovsek S; Komrokji RS
    Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Hosseini MM; Kurtz SE; Abdelhamed S; Mahmood S; Davare MA; Kaempf A; Elferich J; McDermott JE; Liu T; Payne SH; Shinde U; Rodland KD; Mori M; Druker BJ; Singer JW; Agarwal A
    Leukemia; 2018 Nov; 32(11):2374-2387. PubMed ID: 29743719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of pacritinib in the treatment of myelofibrosis.
    Duenas-Perez AB; Mead AJ
    Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatment options for myelofibrosis: focus on pacritinib.
    Chow V; Weissman A; O'Connell CL; Mehrvar A; Akhtari M
    Onco Targets Ther; 2016; 9():2655-65. PubMed ID: 27226728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
    Al-Fayoumi S; Hashiguchi T; Shirakata Y; Mascarenhas J; Singer JW
    J Exp Pharmacol; 2018; 10():9-17. PubMed ID: 29785143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.
    Hart S; Goh KC; Novotny-Diermayr V; Tan YC; Madan B; Amalini C; Ong LC; Kheng B; Cheong A; Zhou J; Chng WJ; Wood JM
    Blood Cancer J; 2011 Nov; 1(11):e44. PubMed ID: 22829080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
    Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian JJ; Lucchesi A; Kong T; Buckley SA; Tyavanagimatt S; Harder BG; Roman-Torres K; Smith J; Craig AR; Mascarenhas J; Verstovsek S
    Blood Adv; 2023 Oct; 7(19):5835-5842. PubMed ID: 37552106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pacritinib for myelofibrosis in adults with thrombocytopenia.
    Yang DH; Lu Q; Zhu Z; Huang G; Young K
    Drugs Today (Barc); 2022 Dec; 58(12):577-589. PubMed ID: 36651066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of pacritinib and its potential in the treatment of hematologic disorders.
    Hatzimichael E; Tsolas E; Briasoulis E
    J Blood Med; 2014; 5():143-52. PubMed ID: 25170285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
    De SK
    Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
    Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
    Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
    Mascarenhas J
    Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.